Melih Yilmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Melih Yilmaz has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- William Stafford Noble
Department of Genome Sciences, University of Washington
5 shared publications - Wout Bittremieux
Department of Computer Science, University of Antwerp
4 shared publications - Kemal Sonmez
Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon
2 shared publications - Lan Guo
Amazon Web Services, Applied AI Solutions, Life Sciences
2 shared publications - Luca Giancardo
McWilliams School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, USA
2 shared publications - Rowan Nelson
Bioinformatics Program, Faculty of Computing and Data Sciences, Boston University, Boston, MA, USA
2 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (11) , 101673
Pretrained Spectrum Representations for Diverse Tandem Mass Spectrometry Proteomics Tasks
- 7 October 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (11) , 101673
Open AccessPretrained Spectrum Representations for Diverse Tandem Mass Spectrometry Proteomics Tasks
- Open Access
Agent-Guided De Novo Design of Nanobody Binders Against a Novel Cancer Target
Therapeutic antibody discovery remains slow and resource-intensive, with traditional methods providing limited control over epitope selection. We present a workflow for de novo nanobody design applied to a novel Desmoplastic Small Round Cell Tumor target encompassing four stages: (1) epitope identification guided by our hotspot recommendation agent using physical chemistry-based structure and sequence analysis tools with two curated databases (IEDB, PFAM), (2) de novo nanobody generation using three independent methods (RFantibody, IgGM, mBER) across multiple predicted antigen structures and nanobody frameworks, (3) multi-metric scoring including structural metrics from folding models, and in silico binding affinity from our sequence-based predictor, (4) high-throughput yeast surface display (YSD) screening followed by surface plasmon resonance (SPR) characterization of the specific binders. We generated 288,000 nanobody designs spanning eight target epitope regions and three variable domains of heavy chain-only antibody (VHH) frameworks. Multi-objective Pareto filtering with our candidate selection agent yielded 100,000 candidates for YSD screening with fluorescence-activated cell sorting (FACS). Of 116 enriched candidates advanced to SPR characterization, 46/116 (39.7%) produced reliable kinetic fits with R max ≥ 30 RU, yielding K D values from 0.66 nM to 305 nM (median 31.7 nM). These results show that an agent-guided computational workflow can design nanomolar to sub-nanomolar nanobody binders against a novel target without experimental structure or prior antibody information.
Open AccessAgent-Guided De Novo Design of Nanobody Binders Against a Novel Cancer Target
Therapeutic antibody discovery remains slow and resource-intensive, with traditional methods providing limited control over epitope selection. We present a workflow for de novo nanobody design applied to a novel Desmoplastic Small Round Cell Tumor target encompassing four stages: (1) epitope identification guided by our hotspot recommendation agent using physical chemistry-based structure and sequence analysis tools with two curated databases (IEDB, PFAM), (2) de novo nanobody generation using three independent methods (RFantibody, IgGM, mBER) across multiple predicted antigen structures and nanobody frameworks, (3) multi-metric scoring including structural metrics from folding models, and in silico binding affinity from our sequence-based predictor, (4) high-throughput yeast surface display (YSD) screening followed by surface plasmon resonance (SPR) characterization of the specific binders. We generated 288,000 nanobody designs spanning eight target epitope regions and three variable domains of heavy chain-only antibody (VHH) frameworks. Multi-objective Pareto filtering with our candidate selection agent yielded 100,000 candidates for YSD screening with fluorescence-activated cell sorting (FACS). Of 116 enriched candidates advanced to SPR characterization, 46/116 (39.7%) produced reliable kinetic fits with R max ≥ 30 RU, yielding K D values from 0.66 nM to 305 nM (median 31.7 nM). These results show that an agent-guided computational workflow can design nanomolar to sub-nanomolar nanobody binders against a novel target without experimental structure or prior antibody information.
- Open Access
Foundation model for mass spectrometry proteomics
Mass spectrometry is the dominant technology in the field of proteomics, enabling high-throughput analysis of the protein content of complex biological samples. Due to the complexity of the instrumentation and resulting data, sophisticated computational methods are required for the processing and interpretation of acquired mass spectra. Machine learning has shown great promise to improve the analysis of mass spectrometry data, with numerous purpose-built methods for improving specific steps in the data acquisition and analysis pipeline reaching widespread adoption. Here, we propose unifying various spectrum prediction tasks under a single foundation model for mass spectra. To this end, we pre-train a spectrum encoder using de novo sequencing as a pre-training task. We then show that using these pre-trained spectrum representations improves our performance on the four downstream tasks of spectrum quality prediction, chimericity prediction, phosphorylation prediction, and glycosylation status prediction. Finally, we perform multi-task fine-tuning and find that this approach improves the performance on each task individually. Overall, our work demonstrates that a foundation model for tandem mass spectrometry proteomics trained on de novo sequencing learns generalizable representations of spectra, improves performance on downstream tasks where training data is limited, and can ultimately enhance data acquisition and analysis in proteomics experiments.
Open AccessFoundation model for mass spectrometry proteomics
Mass spectrometry is the dominant technology in the field of proteomics, enabling high-throughput analysis of the protein content of complex biological samples. Due to the complexity of the instrumentation and resulting data, sophisticated computational methods are required for the processing and interpretation of acquired mass spectra. Machine learning has shown great promise to improve the analysis of mass spectrometry data, with numerous purpose-built methods for improving specific steps in the data acquisition and analysis pipeline reaching widespread adoption. Here, we propose unifying various spectrum prediction tasks under a single foundation model for mass spectra. To this end, we pre-train a spectrum encoder using de novo sequencing as a pre-training task. We then show that using these pre-trained spectrum representations improves our performance on the four downstream tasks of spectrum quality prediction, chimericity prediction, phosphorylation prediction, and glycosylation status prediction. Finally, we perform multi-task fine-tuning and find that this approach improves the performance on each task individually. Overall, our work demonstrates that a foundation model for tandem mass spectrometry proteomics trained on de novo sequencing learns generalizable representations of spectra, improves performance on downstream tasks where training data is limited, and can ultimately enhance data acquisition and analysis in proteomics experiments.
- Open Access
Systematic benchmarking of mass spectrometry-based antibody sequencing reveals methodological biases
The circulating antibody repertoire is crucial for immune protection, holding significant immunological and biotechnological value. While bottom-up mass spectrometry (MS) is the most widely used proteomics technique for profiling the sequence diversity of circulating antibodies (Ab-seq), it has not been thoroughly benchmarked. We quantified the replicability and robustness of Ab-seq using six monoclonal antibodies with known protein sequences in 70 different combinations of concentration and oligoclonality, both with and without polyclonal serum IgG background. Each combination underwent four protease treatments and was analyzed across four experimental and three technical replicates, totaling 3,360 LC-MS/MS runs. We quantified the dependence of MS-based Ab-seq identification on antibody sequence, concentration, protease, background signal diversity, and bioinformatics setups. Integrating the data from experimental replicates, proteases, and bioinformatics tools enhanced antibody identification. De novo peptide sequencing showed similar performance to database-dependent methods for higher antibody concentrations, but de novo antibody reconstruction remains challenging. Our work provides a foundational resource for the field of MS-based antibody profiling.
Open AccessSystematic benchmarking of mass spectrometry-based antibody sequencing reveals methodological biases
The circulating antibody repertoire is crucial for immune protection, holding significant immunological and biotechnological value. While bottom-up mass spectrometry (MS) is the most widely used proteomics technique for profiling the sequence diversity of circulating antibodies (Ab-seq), it has not been thoroughly benchmarked. We quantified the replicability and robustness of Ab-seq using six monoclonal antibodies with known protein sequences in 70 different combinations of concentration and oligoclonality, both with and without polyclonal serum IgG background. Each combination underwent four protease treatments and was analyzed across four experimental and three technical replicates, totaling 3,360 LC-MS/MS runs. We quantified the dependence of MS-based Ab-seq identification on antibody sequence, concentration, protease, background signal diversity, and bioinformatics setups. Integrating the data from experimental replicates, proteases, and bioinformatics tools enhanced antibody identification. De novo peptide sequencing showed similar performance to database-dependent methods for higher antibody concentrations, but de novo antibody reconstruction remains challenging. Our work provides a foundational resource for the field of MS-based antibody profiling.
- Open Access
- 7 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Deep learning methods for de novo peptide sequencing
Protein tandem mass spectrometry data is most often interpreted by matching observed mass spectra to a protein database derived from the reference genome of the sample being analyzed. In many application domains, however, a relevant protein database is unavailable or incomplete, and in such settings de novo sequencing is required. Since the introduction of the DeepNovo algorithm in 2017, the field of de novo sequencing has been dominated by deep learning methods, which use large amounts of labeled mass spectrometry data to train multi-layer neural networks to translate from observed mass spectra to corresponding peptide sequences. Here, we describe these deep learning methods, outline procedures for evaluating their performance, and discuss the challenges in the field, both in terms of methods development and evaluation protocols.
- 7 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDeep learning methods for de novo peptide sequencing
Protein tandem mass spectrometry data is most often interpreted by matching observed mass spectra to a protein database derived from the reference genome of the sample being analyzed. In many application domains, however, a relevant protein database is unavailable or incomplete, and in such settings de novo sequencing is required. Since the introduction of the DeepNovo algorithm in 2017, the field of de novo sequencing has been dominated by deep learning methods, which use large amounts of labeled mass spectrometry data to train multi-layer neural networks to translate from observed mass spectra to corresponding peptide sequences. Here, we describe these deep learning methods, outline procedures for evaluating their performance, and discuss the challenges in the field, both in terms of methods development and evaluation protocols.
- Top Cited PapersOpen Access
- 30 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
Sequence-to-sequence translation from mass spectra to peptides with a transformer model
A fundamental challenge in mass spectrometry-based proteomics is the identification of the peptide that generated each acquired tandem mass spectrum. Approaches that leverage known peptide sequence databases cannot detect unexpected peptides and can be impractical or impossible to apply in some settings. Thus, the ability to assign peptide sequences to tandem mass spectra without prior information—de novo peptide sequencing—is valuable for tasks including antibody sequencing, immunopeptidomics, and metaproteomics. Although many methods have been developed to address this problem, it remains an outstanding challenge in part due to the difficulty of modeling the irregular data structure of tandem mass spectra. Here, we describe Casanovo, a machine learning model that uses a transformer neural network architecture to translate the sequence of peaks in a tandem mass spectrum into the sequence of amino acids that comprise the generating peptide. We train a Casanovo model from 30 million labeled spectra and demonstrate that the model outperforms several state-of-the-art methods on a cross-species benchmark dataset. We also develop a version of Casanovo that is fine-tuned for non-enzymatic peptides. Finally, we demonstrate that Casanovo’s superior performance improves the analysis of immunopeptidomics and metaproteomics experiments and allows us to delve deeper into the dark proteome.
- 30 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
Top Cited PapersOpen AccessSequence-to-sequence translation from mass spectra to peptides with a transformer model
A fundamental challenge in mass spectrometry-based proteomics is the identification of the peptide that generated each acquired tandem mass spectrum. Approaches that leverage known peptide sequence databases cannot detect unexpected peptides and can be impractical or impossible to apply in some settings. Thus, the ability to assign peptide sequences to tandem mass spectra without prior information—de novo peptide sequencing—is valuable for tasks including antibody sequencing, immunopeptidomics, and metaproteomics. Although many methods have been developed to address this problem, it remains an outstanding challenge in part due to the difficulty of modeling the irregular data structure of tandem mass spectra. Here, we describe Casanovo, a machine learning model that uses a transformer neural network architecture to translate the sequence of peaks in a tandem mass spectrum into the sequence of amino acids that comprise the generating peptide. We train a Casanovo model from 30 million labeled spectra and demonstrate that the model outperforms several state-of-the-art methods on a cross-species benchmark dataset. We also develop a version of Casanovo that is fine-tuned for non-enzymatic peptides. Finally, we demonstrate that Casanovo’s superior performance improves the analysis of immunopeptidomics and metaproteomics experiments and allows us to delve deeper into the dark proteome.